Rheumatoid arthritis is characterised by uncontrolled chronic inflammation of the joints, which leads to their destruction and functional disability. It is also associated with increased and early cardiovascular mortality. This is thought to be linked to chronic systemic inflammation, which can lead to accelerated atherosclerosis, and thus earlier and more severe CHD. The beneficial effects of statins in the primary and secondary prevention of CHD are wellestablished. These are not only due to their lipid-lowering properties. Statins have several anti-inflammatory and immunomodulatory effects through which they may modify the inflammatory mechanisms involved in the generation and rupture of atherosclerotic plaques. These effects may also be useful for controlling rheumatoid inflammation. Thus statins may be an important adjunctive therapy in RA, aiming to both reduce joint inflammation and improve cardiovascular outcome. This needs to be tested in randomised controlled trials designed specifically for the purpose.
Get full access to this article
View all access options for this article.
References
1.
SymmonsDPGTurnerWebbR The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002; 41:793–800.
2.
ScottDLDPMSymmonsBLCoultonPopertAJ.Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; 1:1108–11.
3.
PincusTCallahanLF.Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13:841–5.
KrootEJJAAMVan GestelSwinkelsHL Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. J Rheumatol 2001; 28:1511–7.
7.
KitasGDMJBanksBaconPA.Cardiac involvement in rheumatoid disease. Clin Med 2001; 1:18–21.
8.
McEntegartAHACapellRMadhokGDOLoweARumleyWoodwardM. Cardiovascular (CVS) Risk factors in an RA population. Rheumatology 2000; 39:40.
9.
ErbNAVPace,Douglas KJM, Banks M, Kitas GD. Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2004; 33:293–9.
10.
SitunayakeRDDyslipidaemiaKitas GD. and rheumatoid arthritis. Ann Rheum Dis 1997; 56:341–2.
11.
del Rincon ID, Williams K, Stern MP High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737–45.
12.
ChoyEHSPanayiGS.Cytokine pathways and joint inflammation in rheumatoid arthritis. N Eng J Med 344; 12:907–16.
SattarNDWMcCareyHCapellMcInnesIB.Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108(24):2957–63.
15.
Wallberg-JonssonSHJohanssonMLOhmanRantapaa-DahlqvistS. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999; 26:2562–71.
16.
PincusTCallahanLF.Rheumatology function tests: grip strength, walking time, button test and questionnaires document predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol 1992; 19:1051–7.
17.
JacobssonLTCTuressonHansonRL Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 2001; 44:1170–6.
18.
ChehataJCABHassellClarkeSA Mortality in rheumatoid arthritis: relation to single and composite measures of disease activity. Rheumatology 2001; 40:447–52.
19.
PincusTLFCallahanSaleWG Severe functional declines, work disability and increased mortality in 75 rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27:864–72.
20.
Wallberg-JonssonSMLOhmanRantapaa-DahlqvistS. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24:445–51.
21.
ChoiHKMAHermanJDSeegerJMRobinsMethotrexateWolfe F.inmortality patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173–7.
22.
MitchellDMPWSpitz,Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29:706–14.
23.
LehtinenKIsomakiH. Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis. J Rheumatol 1991; 18:524–9.
24.
KrauseDBSchleusserGHerbornRauR. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14–21.
25.
BaconPAKRazaMJBanksJTownendKitasGD.The role of endothelial cell dysfunction in the cardiovascular mortality of RA. Int Rev Immunol 2002; 21(1):1–17.
26.
RossR.Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340:115–27.
27.
KitasGDMJBanksBaconPA.Accelerated atherosclerosis as a cause of cardiovascular death in RA. Pathogenesis 1998; 1(2):73–83.
28.
DaneshJPWhincupMWalkerLennonL Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321:199–204.
29.
MorrowDAC-reactive proteinRidker PM., inflammation and coronary risk. Med Clin N Am 2000; 84:149–61.
30.
LucasADGreavesDR.Atherosclerosis: Role of chemokines and macrophages. Exp Rev Mol Med 2001; 1–18. www-ermm.cbcu.cam.ac.uk/01003696h.htm
31.
Yla-HerttualaSBLiftonRosenfeldM Expression of MCP-l in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Nat Acad Sci USA 1991; 88:5252–56.
32.
NelkenNSCoughlinDGordonWilcoxJ. MCP-l in human atheromatous plaques. J Clin Invest 1991; 88:1121–7.
33.
StemmeSJHolmHanssonGK.T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992; 12:206–11.
34.
HanssonGKMHellstrandLRymoLRubbiaGabbianiG. Interferon-? inhibits both proliferation and expression of differentiation-specific a-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989; 170:1595–1608.
35.
AmentoEPNEhsaniHPalmerCytokinesLibby P.factorsgrowth positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arteriosler Thromb 1991; 11:1223–30.
36.
LiuzzoGLMBiasucciGallimoreJR The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331:417–24.
37.
HaverkateFSGThompsonSDMPykeJRGallimorePepysMB.Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349:462–6.
38.
Danesh J,Whincup P,Walker M Low grade inflammation and coronary heart disease: prospective study and meta-analysis. BMJ 2000; 321:208–13.
39.
DaneshJJMuir,Wong YK,Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins: a population based study. Eur Heart J 1999; 20:954–9.
40.
Danesh J,Wheeler JG, Hirshfield GM C reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New Eng J Med 2004; 350:1387–97.
41.
Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383–1389.
42.
ShepherdJMCobbe SFordI Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301–1307.
43.
SacksFMMAPfefferMoyeLA The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001–1009.
44.
Heart Protection Study collaboration group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326):7–22.
45.
ShepherdJ.Lipids in health and disease. Biochem Soc Trans 2004; 32(Pt 6):1051.
46.
VaughanCJMBMurphyBuckleyBM.Statins do more than just lower cholesterol. Lancet 1997; 348:1079–82.
47.
PadgettRCDDHeistadAMuggeMLArmstrongDJPiegorsLopezJAG.Vascular responses to activated leukocytes after regression of atherosclerosis. Circ Res 1992; 70:423–9.
48.
SmallDM.George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis 1988; 8:103–29.
49.
LoreeHMBJTobiasLJGibsonRDKammDMSmallLeeRT.Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 1994; 14:230–4.
50.
EhrensteinMRECJury,Mauri C. Statins for atherosclerosis – As good as it gets? N Eng J Med 2005; 352(1):73–5.
51.
CuttsJLBankhurstAD.Suppression of lymphoid cell function in vitro by inhibition of HMG CoA reductase by lovastatin. Int J Immunopharmac 1989; 11:863–869.
52.
CuttsJLTJScallen,Watson J, Bankhurst AD. The role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139:550–7.
53.
KobashigawaJSKatznelsonLaksH Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333:621–627.
54.
LibbyPPMRidkerInflammationMaseri A. and atherosclerosis. Circulation 2002; 105:1135–43.
55.
Rosensen R,Tangney CC, Casey LC. Inhbition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353:983–4.
56.
RidkerPMNRifaiMAPfefferFSacksBraunwaldE. Long-term effects of pravastatin on plasma concentration of C-reactive protein.The CARE Investigators. Circulation 1999; 100:230–5.
57.
JialalIDSteinDBalisSMGrundyBAdams-HuetDevarajS. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933–5.
58.
AlbertMAJStaggersPChewRidkerPM.The pravastatin inflammation CRO evaluation (PRINCE): rationale and design. Am Heart J 2001; 141:893–8.
59.
RidkerPMCPCannon,Morrow D, Rifai N C-reactive protein levels and outcomes after statin therapy. N Eng J Med 352; 1:20–8.
60.
DavignonJMabileL. Mechanisms of action of statins and their pleiotropic effects. Ann Endocrinol 2001; 62:101–112.
61.
Martin G Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107:1423–32.
62.
AlbertMAEDanielsonNRifaiRidker PM;PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64–70.
63.
OrtegoMCBustosMAHernandez-PresaJTunonCDiazGHernandezEgidoJ. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147:253–61.
64.
PahanKFGSheikhAMNamboodiriLovastatinSingh I.inhibitphneylacetate the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100:2671–9.
65.
KotheHKDalhoffRuppJ Hydroxymethylglutaryl conezyme A reductase inhibitiors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101:1760–3.
66.
InoueISGotoMizotaniK Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1ß, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor-a (PPAR-a) in primary endothelial cells. Life Sci 2000; 67:863–876.
67.
KwakBFMulhauptSMyitMachF. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399–1402.
68.
Weitz-Schmidt G Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687–92.
69.
McCartyMF.Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. Med Hypotheses 2003; 60(5):634–9.
70.
NissenSEEMurat TuzcuPSchoenhagenCroweT Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Eng J Med 2005; 352(1):29–38.
71.
McCareyDWIBMcInnesRMadhokHampsonR Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised, placebo-controlled trial. Lancet 2004; 363:2015–21.
72.
StevensRKDouglasASaratzisInflammationKitas GD.inatherosclerosis rheumatoid arthritis. Exp Rev Molec Med 2005; 7:1–24.
